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 1. ABSTRACT 
 
The ability to recognize facial emotion expressions, especially negative ones, is 
described to be impaired in Parkinson's disease (PD) patients. Previous 
neuroimaging work evaluating the neural substrate of facial emotion recognition 
(FER) in healthy and pathological subjects has mostly focused on functional 
changes. This study was designed to evaluate gray matter (GM) and white 
matter (WM) correlates of FER in a large sample of PD. Thirty-nine PD patients 
and 23 healthy controls (HC) were tested with the Ekman 60 test for FER and 
with magnetic resonance imaging. Effects of associated depressive symptoms 
were taken into account. In accordance with previous studies, PD patients 
performed significantly worse in recognizing sadness, anger and disgust. In PD 
patients, voxel-based morphometry analysis revealed areas of positive 
correlation between individual emotion recognition and GM volume: in the right 
orbitofrontal cortex, amygdala and postcentral gyrus and sadness identification; 
in the right occipital fusiform gyrus, ventral striatum and subgenual cortex and 
anger identification, and in the anterior cingulate cortex (ACC) and disgust 
identification. WM analysis through diffusion tensor imaging revealed significant 
positive correlations between fractional anisotropy levels in the frontal portion of 
the right inferior fronto-occipital fasciculus and the performance in the 
identification of sadness. These findings shed light on the structural neural 
bases of the deficits presented by PD patients in this skill. 
 
 
 
 
 
 
 
 
 2. INTRODUCTION 
 
Parkinson’s disease (PD) is more typically characterized by its motor 
features. In recent years, however, the interest in its non-motor manifestations 
has increased significantly. Among these manifestations, cognitive deficits are 
commonly found even in recently diagnosed PD patients. Memory and 
executive function are the most prominently, but not the only, affected domains 
(Muslimovic, Post, Speelman & Schmand, 2005). The capacity to accurately 
identify emotions in others' facial expressions, a skill of great importance for 
normal social interaction, has been described in several studies to be impaired 
in PD (Yip, Lee, Ho, Tsang & Li, 2003; Dujardin et al., 2004; Kan, Kawamura, 
Hasegawa, Mochizuki & Nakamura, 2002; Ariatti, Benuzzi & Nichelli, 2008; 
Sprengelmeyer et al., 2003; Lawrence, Goerendt & Brooks, 2007; Suzuki, 
Hoshino, Shigemasu & Kawamura, 2006), though somewhat inconsistently. 
While most of these studies suggest a selective deficit in identifying negative 
emotions, results vary as to which specific emotions have their identification 
selectively or predominantly affected. Still other studies failed to identify any 
facial emotion recognition impairments in PD patients (Pell and Leonard, 2005; 
Dujardin et al., 2004; Biseul et al., 2005). These different results might be due to 
different evaluation methods, as well as to different patient samples with respect 
to relevant variables such as age, education, medication status, cognitive 
impairment and disease severity or duration. Furthermore, not all studies have 
taken into account the presence of associated depressive disorders, present in 
up to 50% of PD patients (Reijnders, Ehrt, Weber, Aarsland & Leentjens, 2008; 
Slaughter, Nichols, Holmes & Martens, 2001), which also lead to facial emotion 
recognition (FER) deficits (Leppanen, 2006).  
The finding that pathological processes such as PD, depression or 
Huntington's disease (Calder et al., 2010) may cause deficits in the identification 
of specific emotions, as well as data obtained from functional neuroimaging and 
electrophysiological studies and studies with patients with focal lesions indicate 
that the recognition of different emotions relies on different (Adolphs, Tranel & 
Damasio, 2003; Fusar-Poli et al., 2009; Calder, Keane, Manes, Antoun & 
Young, 2000; Krolak-Salmon et al., 2003; Adolphs et al., 2002; Adolphs, Tranel, 
Damasio & Damasio, 1994; Calder et al., 1996; Phillips et al., 1997) though 
overlapping neural substrates (Heberlein, Padon, Gillihan, Farah & Fellows, 
2008; Hornak et al., 2003; Adolphs, Damasio, Tranel, Cooper & Damasio, 
2000).  
Most published neuroimaging studies concerning the neural substrate of 
emotional processing used functional techniques. Knowledge about the ability 
of MRI to identify structural correlates for individual emotion recognition is very 
limited, both in pathological and in healthy subjects samples. In the specific 
case of PD patients, only one published work addressed structural correlates of 
FER deficits. In this study, done by our group, gray matter (GM) volumes in the 
amygdalae and orbitofrontal cortex (OFC) were found to correlate positively with 
overall emotion recognition (Ibarretxe-Bilbao et al., 2009). The neural substrate 
of the recognition of individual emotions, however, was not studied. 
Besides the better-studied GM changes in PD, there is increasing 
evidence that white matter (WM) microstructural changes detectable by 
magnetic resonance diffusion tensor imaging techniques occur early in the 
course of the disease (Gattellaro et al., 2009; Karagulle Kendi, Lehericy, 
Luciana, Ugurbil & Tuite, 2008) and that WM changes may contribute to 
cognitive deficits by means of impaired connectivity (Vernooij et al., 2009). 
There is little knowledge, however, about how such changes may relate to facial 
emotion recognition deficits. 
Our aim in the present work was to study the relationship between the 
capacity to recognize specific emotions in facial expressions and gray and white 
matter structural parameters evaluated through state-of-the-art MRI techniques 
in a large sample of non-demented PD patients.  
 
 
3. METHODS 
 
3.1 Subjects 
Thirty-nine PD patients and 23 age-matched healthy controls (HC) were 
included. Patients were recruited from the Movement Disorders Unit, Neurology 
Department, Hospital Clínic, in Barcelona. The inclusion criterion was the 
fulfillment of the UK PD Society Brain Bank (PDSBB) diagnostic criteria for PD 
(Daniel & Lees, 1993). The exclusion criteria were: (i) presence of dementia 
according to the Movement Disorders Society criteria (Emre et al., 2007), (ii) 
presence of Beck Depression Inventory-II scores higher than 16, suggested as 
a specific cut-off point for diagnosing depression in PD patients by Leentjens, 
Verhey, Luijckx & Troost (2000), (iii)  presence of other significant psychiatric or 
neurological comorbidity, (iv) pathological magnetic resonance imaging findings 
other than mild WM hyperintensities in long-TR sequences or those that could 
be related to PD. 
All PD patients were taking antiparkinsonian drugs, consisting of different 
combinations of L-dopa (n=11), L-dopa with COMT inhibitors (n=12), MAO 
inhibitors (n=10), dopamine agonists (n=17) and amantadine (n=4). The 
medication was not changed for the study and all assessments were done while 
patients were in the on state. To evaluate possible medication effects, levodopa 
equivalent daily doses were calculated as suggested by Tomlinson et al. (2010). 
The study was approved by the ethics committee of the University of 
Barcelona, and all subjects provided written informed consent to participate. 
 
3.2 Neuropsychological assessment 
All subjects underwent a thorough neuropsychological battery to assess the 
cognitive functions more frequently impaired in non-demented PD patients: 
memory, visuospatial, visuoperceptive and executive functions (Muslimovic, 
Post, Speelman & Schmand, 2005; Foltynie, Brayne, Robbins & Barker, 2004; 
Aarsland et al., 2009). In addition to the Mini-Mental State Examination 
(MMSE), we administered the following tests: Rey Auditory Verbal Learning 
Test, Digits subset of the Wechsler Adults Intelligence Scale (WAIS-III), Stroop 
Color-Word Test, phonemic and semantic fluencies, Trail Making Tests A and B, 
Benton’s Visual Form Discrimination Test and Judgment of Line Orientation 
Test, and Visual Object and Space Perception Battery (Lezak, Howieson, & 
Loring, 2004). We also administered the Cumming’s Neuropsychiatric Inventory 
(Cummings et al., 1994) and the Beck Depression Inventory-II (Beck, Steer & 
Brown, 1996) to identify neuropsychiatric symptoms associated with PD. 
 
3.3 Facial emotion recognition assessment 
All subjects were tested with the Ekman 60 test for recognition of 
emotions in facial expressions. In this test, 60 pictures of faces from the Ekman 
and Friesen series of Pictures of Facial Affect (Ekman & Friesen, 1976) are 
presented consecutively. The subject is required to the label each picture as to 
the emotion predominantly expressed in it from a list of six possible choices 
(anger, fear, sadness, disgust, happiness and surprise, translated to Spanish as 
enfado, miedo, tristeza, asco, alegría y sorpresa, respectively). Each 
photograph is shown on a computer screen for 5 seconds, but there is no time 
limit to make the choice.  
Each of the six individual emotions is represented in ten out of the total 
sixty pictures. Results are presented in number of correct answers out of 10 for 
each emotion and in total correct answers out of 60 for total Ekman scores. 
 
3.4 Statistical analysis 
Analyses were carried out using the PASW Version 17.0.2 (SPSS, Inc., 
Chicago, IL, USA). Group differences in demographic, clinical and 
neuropsychological characteristics were analyzed with independent two-tailed 
Student’s t-tests for normally-distributed variables, the Mann-Whitney U test for 
non-normally distributed ones, and the chi-squared test for categorical 
variables. To control for possible effects of associated depressive symptoms 
and cognitive decline when measuring differences between Ekman test results 
between groups, BDI and MMSE scores were entered as covariates in two-level 
analyses of covariance (ANCOVAs). Associations between demographic, 
clinical and cognitive variables and FER scores were analyzed using Pearson’s 
correlation for normally distributed variables and Spearman’s rank correlations 
for those that did not present a normal distribution. Statistical significance 
threshold was set at p<0.05. 
 
3.5 Image acquisition and analysis 
Magnetic resonance images were acquired with a 3T scanner (TIM Trio, 
Siemens, Germany). High-resolution 3-dimensional T1-weighted images were 
acquired in the sagittal plane (TR 2300 ms, TE 2.98 ms, TI 900 ms; 256 x 256 
matrix, 1 mm isotropic voxel). Sagittal diffusion tensor images were obtained 
using a single-shot EPI sequence (TR 5533 ms, TE 88 ms), with diffusion 
encoding in 30 directions at b = 0 and 1000 s/mm2. 
Structural data was analyzed with FSL-VBM (Douaud et al., 2007), a 
voxel-based morphometry-style analysis carried out with FSL tools. First, 
nonbrain tissue from structural images was extracted. After segmentation, GM 
images were aligned to MNI152 standard space using affine registration. The 
resulting images were averaged to create a study-specific template, to which 
the native GM images were then non-linearly re-registered. The registered 
partial volume images were then modulated (to correct for local expansion or 
contraction) by dividing by the Jacobian of the warp field. The modulated 
segmented images were then smoothed with an isotropic Gaussian kernel with 
a sigma of 3 mm. Finally, voxelwise general linear model was applied using 
permutation-based non-parametric testing, correcting for multiple comparisons 
across space. 
Voxelwise statistical analysis of the fractional anisotropy (FA) data was 
carried out using TBSS (Tract-Based Spatial Statistics, [Smith, 2006]), part of 
FSL (Smith et al., 2004). First, FA images were created by fitting a tensor model 
to the raw diffusion data using FDT, and then brain-extracted using BET (Smith 
et al., 2002). All subjects' FA data were then aligned into a common space using 
the nonlinear registration tool FNIRT (Andersson et al., 2007a, 2007b), which 
uses a b-spline representation of the registration warp field (Rueckert et al., 
1999). Next, the mean FA image was created and thinned to create a mean FA 
skeleton which represents the centers of all tracts common to the group. Each 
subject's aligned FA data was then projected onto this skeleton and the 
resulting data fed into voxelwise cross-subject statistics. 
Structures used as regions of interest (ROIs) for GM analysis were 
chosen based on literature about the neural substrate of emotion processing, 
which includes data from lesion studies and functional MRI studies (Adolphs, 
2002; Fusar-Poli et al., 2009; Adolphs et al., 2000; Calder, Keane, Lawrence & 
Manes, 2004). All GM structures were evaluated bilaterally. The masks for the 
GM ROI analyses were created based on the Harvard-Oxford probabilistic 
cortical and subcortical atlases (Smith et al., 2004). For WM masks, some tracts 
used as ROIs were chosen based on previous studies indicating their relevance 
in emotional processing, such as the inferior fronto-occipital fasciculus and the 
inferior longitudinal fasciculus (Philippi, Mehta, Grabowski, Adolphs & Rudrauf, 
2009; Rudrauf et al., 2008). We also included associative tracts that are 
anatomically connected to the cortical or subcortical structures we included as 
ROIs for the GM analysis, to investigate possible structural connectivity 
abnormalities between areas critical for emotion processing. The Johns Hopkins 
University white-matter tractography atlas was used to create the WM tract 
masks, which were evaluated bilaterally. Both atlases are available in FSL 
(http://www.fmrib.ox.ac.uk/fsl/data/atlas-descriptions.html). For GM analyses, 
the ROIs used were:  
 
OFC Insula 
Anterior cingulate cortex (ACC) Parahippocampal gyrus (PHG) 
Striatum Ventromedial prefrontal cortex 
Postcentral gyrus (PCG) Amygdala 
Hippocampus Inferior and middle frontal gyri 
Fusiform gyrus  
 
For WM analysis, the tracts used as ROIs were: 
 
Inferior fronto-occipital fasciculus (IFOF) Uncinate fasciculus 
Superior longitudinal fasciculus (SLF) Cingulum 
Inferior longitudinal fasciculus (ILF) Forceps minor 
 
Statistical significance threshold was set at p<0.05, corrected for multiple 
comparisons through familywise error (FWE) correction (Worsley et al., 1996). 
For all correlation analyses, BDI scores were entered as covariates of no 
interest. Analyses of correlation between FER scores and structural parameters 
were repeated adding age as another covariate of no interest. Correlation 
coefficients (r) were calculated using mean GM volume or FA levels from the 
whole clusters rather than from the maxima to avoid the non-independence 
error. 
 
 
 
 
  
4. RESULTS  
 
4.1 Subjects  
 There were no significant differences in age, gender or years of 
education between groups. Demographical and clinical results with group 
comparisons can be seen in Table 1. No subjects fulfilled the Movement 
Disorders Society criteria for dementia (Emre et al., 2007).  
Table 2 shows neuropsychological assessment results with group 
comparisons. For the evaluation of visuospatial/visuoperceptive function, part of 
the sample (11 HC, 22 PD patients) was administered Benton’s Visual Form 
Discrimination and Judgment of Line Orientation tests, whereas another part 
(12 HC, 17 PD patients) was administered Visual Object and Space Perception 
Battery Silhouettes test. No significant differences were observed between HC 
and PD patients’ scores in these subsamples (p>0.05). 
 
4.2 Facial emotion recognition 
As can be seen in Table 3, PD patients' total Ekman test scores and 
subscores in the identification of fear, sadness, anger and disgust were 
significantly lower than controls'. Happiness scores were similar in the two 
groups, and a ceiling effect was observed for this emotion. Scores for the 
identification of surprise were lower in PD patients, approaching statistical 
significance. There were significant effects of group in the two-level ANCOVAs, 
using BDI and MMSE scores as covariates, for the identification of facial 
expressions of anger, sadness and disgust, as well as for total Ekman scores. 
No significant correlations were found between individual emotion 
recognition subscores or total Ekman scores and clinical variables such as 
disease duration, motor severity scales (Hoehn and Yahr [HY] and UDPRS) or 
levodopa equivalent daily dose (LEDD) (see Table 4). 
 
4.3 Gray matter analysis 
Correlation analyses between GM volume and emotional Ekman 60 test 
subscores:  
Whole-brain voxelwise analysis: this analysis showed no significant 
correlations between Ekman test scores and GM volume.  
ROI analysis, sadness scores: significant positive correlations were 
found between patients’ sadness scores and GM volume in the right OFC – a 
small cluster in its lateral portion, corresponding to Brodmann areas 11/47, and 
a medial cluster in the transition of Brodmann areas 11 and 14 –, in the medial 
part of the right amygdala, and in the dorsal part of the right postcentral gyrus 
(p<0.05, FWE-corrected) (Figure 1, A-C).  
ROI analysis, anger scores: anger scores correlated positively with GM 
volume in the ventral striatum bilaterally (nuclei accumbens), in the right 
occipital fusiform gyrus and in the subgenual cortex (Brodmann areas 25 and 
32) (Figure 1, D-F). 
ROI analysis, disgust scores: a positive correlation was found between 
disgust scores and GM volume in the dorsal ACC (Brodmann area 24) (p<0.05, 
FWE-corrected) (Figure 1, G-I). 
ROI analysis, total Ekman scores: total emotion recognition scores 
correlated positively with GM volume in the dorsal ACC, in an area that partially 
overlaps the cluster of significant correlation between GM volume and disgust 
scores (p<0.05, FWE-corrected) (Figure 1, H-I). Correlations between GM 
volume and Ekman scores in this area remained significant even after 
subtracting disgust scores from total Ekman scores (r=0.35, p=0.03). 
Intergroup analyses revealed that PD patients had significantly reduced 
GM volumes compared with controls in all of the clusters described above, 
except in the right nucleus accumbens (Table 5, Supplementary Figure 1). The 
location of the maxima of the clusters of significant correlation as well as their 
volumes and correlation coefficients are presented in Table 5.  
When adding age as a covariate of no interest, all correlations remained 
significant (p<0.05, FWE-corrected) with the exception of those between right 
amygdala GM volume and sadness scores (p=0.12, FWE-corrected), between 
right lateral OFC GM volume and sadness scores (p=0.09, FWE-corrected), and 
between total Ekman scores and ACC GM volume (p=0.06, FWE-corrected). 
 
4.4 White matter analysis 
Correlation analysis between FA and Ekman 60 test subscores in PD 
patients: Whole-FA skeleton voxelwise analysis revealed a strong positive 
correlation between sadness scores and FA levels in a cluster in the right frontal 
lobe WM, with its maximum located in the topography of the inferior fronto-
occipital fasciculus but also involving the forceps minor and body of the corpus 
callosum (Figure 2 A-C). Intergroup analysis revealed that PD patients had 
significantly lower FA levels in this cluster than HC (Table 6, Supplementary 
Figure 1).  
A smaller cluster was observed at the body of the corpus callosum 
extending to the left centrum semiovale (p<0.05, FWE-corrected). In this region, 
FA levels in PD patients were not significantly different from those of the control 
group (Table 6 and Figure 2B). 
ROI analysis revealed additional areas of correlation between FA levels 
and sadness scores in the left temporal lobe white matter, comprising the 
topographies of the inferior fronto-occipital fasciculus and the inferior 
longitudinal fasciculus (Table 6 and Figure 2) (p<0.05, FWE-corrected). There 
were, however, no significant differences in FA levels between groups in these 
topographies.  
All the correlations described above remained statistically significant after 
correcting for patient age (p<0.05, FWE-corrected). No correlations were found 
between FA and other Ekman subscores or total Ekman scores either in whole-
FA skeleton or in ROI analyses.  
 
5. DISCUSSION  
 
In the present study, we found an overall impairment in FER in PD 
patients as this group's total Ekman test scores were significantly lower than 
those of the control group. Analyzing the performance for each emotion 
separately, PD patients presented an impaired recognition of all the negative 
emotions assessed, whereas no differences were observed for the recognition 
of surprise and happiness. Controlling for the potential confounding effects of 
associated mood changes and cognitive decline, however, performance in the 
recognition of all the negative emotions with the exception of fear (anger, 
sadness and disgust) remained significantly worse in PD patients than in HC. 
 As has also been observed in other studies (Suzuki et al., 2006; 
Ibarretxe-Bilbao et al., 2009; Kan et al., 2002), a ceiling effect was observed for 
happiness, and fear was the least accurately identified emotion, both by HC and 
PD patients. 
Given the multiple roles played by dopamine in distinct neural systems 
and the fact that the affectation of dopamine pathways in PD is heterogeneous 
and variable from one patient to another, dopaminergic medication can either 
have a corrective or an overdosing effect, depending on the structure or 
function evaluated (Gotham, Brown & Marsden, 1987; Delaveau et al., 2009). 
Previous work has evidenced that dopamine manipulations can alter FER 
(Lawrence, Calder, McGowan, & Grasby, 2002; Lawrence et al., 2007) or 
modulate the activity of structures involved in it (Delaveau, Salgado-Pineda, 
Wicker, Micallef-Roll & Blin, 2005; Cools, Lewis, Clark, Barker & Robbins, 
2007). In our sample, however, there was no relationship between levodopa 
equivalent daily dose and performance in the recognition of any individual 
emotion or overall emotion recognition. 
We found several brain regions where GM volume correlated positively 
with the ability to identify individual emotions – specifically, the same emotions 
PD patients did worse at recognizing than healthy controls –, and where 
patients presented GM loss compared with controls. Though depressive 
symptoms are known to be a cause of FER impairments (Leppanen, 1996), 
these were taken into account in our analyses. A posteriori analyses showed no 
correlation between severity of depressive symptoms and GM parameters in the 
regions where the latter correlated with FER. 
The impaired recognition of sadness was associated with GM loss in two 
areas of the right OFC – a medial area and a smaller, more lateral one –, in the 
dorsal part of the right postcentral gyrus and in the medial right amygdala. All of 
these areas have been implicated in the recognition of emotions, especially 
negative ones (Adolphs, 2002; Fusar-Poli et al., 2009). The orbitofrontal cortex 
plays a role in FER through different potential mechanisms, such as top-down 
perceptual processing modulation or through motor or somatosensory 
simulation of the observed state (Adolphs, 2002). Also, the critical role played 
by the right somatosensory cortex in facial emotion recognition, evaluated in 
lesion (Adolphs et al., 2000) as well as transcranial magnetic stimulation studies 
(Pitcher, Garrido, Walsh & Duchaine, 2008), supports the hypothesis that 
representation in this cortical area is critical for FER. These findings lend 
support to simulationist theories of emotion recognition, according to which the 
identification of a given emotion relies on the reactivation of sensorimotor 
networks involved in experiencing it (Niedenthal, 2007; Goldman & Sripada, 
2005).  
Performance in the recognition of anger correlated with GM volume in the 
right occipital fusiform gyrus, in the subgenual cortex and in the ventral striatum 
(nuclei accumbens). These findings are consistent with a study by Calder et al. 
(2004), in which patients with damage to the ventral striatal area were shown to 
have a disproportionate impairment in the recognition of this emotion.  
The fusiform gyrus is classically implicated in the processing of static 
features of faces and in the recognition of identity (Kanwisher, McDermott & 
Chun, 1997; Adolphs, 2002). It also appears to play a role in the processing of 
emotional faces, although its activation has not usually been described to be 
associated specifically with the presentation of angry ones in functional studies 
(Fusar-Poli et al., 2009). The subgenual cortex is part of the so-called emotional 
subdivision of the ACC, and is involved in the evaluation of emotional salience 
of stimuli and in the regulation of emotional responses (Bush, Luu & Posner, 
2000).  
Previous work has evidenced that patients with lesions in ventromedial 
prefrontal cortical areas (including those we found to correlate with the 
identification of sadness and anger in PD patients) may have an impaired ability 
to process the affective attributes of emotional stimuli or to experience the 
emotion associated with these stimuli (Bechara, Damasio & Damasio, 2000), 
both of which might lead to the incorrect identification of emotions in others. Our 
results indicate that distinct parts of the ventromedial prefrontal cortex may play 
different roles in the processing of specific emotions. 
GM volume in the dorsal ACC correlated positively with the identification 
of disgust. Though this area has classically been considered as part of the 
“cognitive” subdivision of the ACC, this dichotomic view restricting emotional 
processing to the ventral anterior cingulate has been called into question (Etkin, 
Egner & Kalisch, 2011). In fact, a similar part of the dorsal ACC was seen to be 
activated while healthy subjects watched facial expressions of disgust and also 
when they experienced this emotion themselves in the study by Wicker et al. 
(2003).  
Some of the pictures used in the Ekman 60 test are somewhat 
ambiguous, and the subject must weigh the conflicting information and 
determine which emotion predominates. The dorsal ACC is also involved in 
emotional conflict resolution (Etkin et al., 2011; Egner, Etkin, Gale & Hirsch, 
2007), and might therefore be engaged in this kind of task. Indeed, we found 
that the dorsal ACC GM volume correlates with overall Ekman performance. 
When entering age as a covariate, statistical significance was lost for the 
correlations between sadness identification and both right amygdala and right 
lateral orbitofrontal cortex GM, and between total Ekman scores and ACC GM, 
though a trend remained for the last two. This could at first glance suggest that 
the observed effects are a result of aging rather than of PD; in our sample, 
however, patient’s age did not correlate with the performance in identifying 
sadness. In fact, this is in line with the proposed biologic interaction between 
age and the pathological effects of PD on GM neuronal loss in non-
dopaminergic structures (Levy, 2007). According to this model, brain structures 
more affected by PD (including the medial temporal lobe, the ACC and the 
OFC) would present age-related changes earlier than other structures, so that 
correcting for the effects of aging might also obscure PD-related effects. More 
studies are necessary to evaluate this effect in neuroimaging analyses.  
It is noteworthy that group comparisons in the areas described above 
revealed GM loss in structures such as the occipital fusiform gyrus and the 
precentral gyrus in PD patients compared to HC. According to the progression 
model proposed by Braak, Ghebremedhin, Rüb, Bratzke and Del Tredici (2004), 
these structures should be affected by α-synucleinopathy late in the disease 
course – later than structures such as the right ventral striatum, where GM 
volume loss was not present – , and our sample was not composed of patients 
with advanced disease. It might however be misleading to expect GM loss 
patterns to correspond rigidly to the six-stage model proposed by Braak et al. 
(2004) of ascending Lewy body pathology. Not only because up to 43% of PD 
cases may fail to conform to this model (Jellinger, 2008), but also because PD-
related factors other than synucleinopathy could lead to neuronal death. Long-
term loss of cholinergic input secondary to nucleus basalis magnocellularis 
lesion in rats is associated with frontoparietal cortical, hippocampal and 
amygdalar atrophy (Arendash, Millard, Dunn & Meyer, 1987). The equivalent 
nucleus in humans is affected relatively early in the course of PD (Braak et al., 
2004). To our knowledge, however, the relationship between loss of cholinergic 
innervation and regional atrophy in PD has not been adequately studied, so this 
remains speculative. Another important contributor to cognitive dysfunction in 
PD is the coexistence of Alzheimer-type pathology (Jellinger, Seppi, Wenning & 
Poewe, 2002). The association of Lewy and Alzheimer-type pathologies has 
recently been found to be strongly associated with dementia in PD (Compta et 
al., 2011), and could conceivably be associated with specific patterns of 
neuronal loss. 
Recent neuroimaging studies point to the existence of early WM 
degeneration in PD (Gattellaro et al., 2009; Karagulle Kendi et al., 2008), and 
basic research studies support this. While it might be tempting to think that 
axonal changes would be a result of α-synucleinopathy-induced neuronal death 
and therefore a late finding in the disease course, recent evidence suggests 
that axonal degeneration may precede neuronal cell body death, and may 
contribute importantly to the manifestations of neurodegenerative diseases, 
including PD (Raff, Whitmore & Finn, 2002; Conforti, Adalbert & Coleman, 2007; 
Hilliard, 2008). Additionally, axons may present inflammatory changes even 
before degenerating, as suggested by an animal study with mutant α-synuclein 
transgenic mice which revealed early widespread axonal swelling (Martin et al., 
2006). A similar process could feasibly take place in PD patients, in whom 
extensive axonal α-synuclein inclusions have been described (Braak, 
Sandmann-Keil, Gai, Braak, 1999). Taken together, these findings suggest that 
WM changes might occur independently from GM changes in PD, and at its 
early stages. FA decrements are a sensitive marker of WM degeneration, and 
may be related to axonal loss, demyelination or edema (Lu et al., 2004); as 
such, they could represent a useful marker for detecting these changes at an 
early stage. 
We have found an area in the right frontal lobe where FA levels 
correlated with the performance in identifying facial expressions of sadness and 
were reduced compared to controls’. The fasciculus mostly affected was the 
IFOF, which runs from the frontal lobes to the parietal, temporal and occipital 
lobes and is usually considered to be implicated in semantic processing 
(Martino, Brogna, Robles, Vergani & Duffau, 2010; Duffau et al., 2005). 
Recently, however, Philippi et al. (2009), studying patients with focal brain 
lesions, described overall impairments in FER associated with damage to the 
right IFOF, more specifically in the recognition of fear, anger and sadness. 
These results indicate that the IFOF has an important role in emotional 
processing, as might be reasonably surmised since it connects areas such as 
the OFC, the medial temporal lobe and the insula to the visual cortex. Our 
findings provide neuroimaging evidence that the integrity of the IFOF is critical 
for the processing of facial emotions.  
Besides the structures discussed above, we also found significant 
correlations between anger recognition and GM volume in the right ventral 
striatum, and between sadness recognition and FA levels in the temporal part of 
the left IFOF and ILF, but no group differences in these structural parameters 
could be found in these regions. Though we cannot exclude that disease-
related degenerative processes in these structures might be contributing to FER 
impairments in some patients, these findings could also represent a 
physiological correlate of the recognition of these emotions. 
Structural techniques may have limitations when studying anatomic 
correlates for functional deficits such as the ones addressed in this study. It has 
been demonstrated that cognitive deficits in PD do not correlate with Lewy body 
and Lewy neurite pathology (Jellinger, 2008), and that neurons affected by α-
synucleinopathy probably cease to function long before dying (Braak et al., 
2004). The same could be the case for Alzheimer-type pathology. Changes in 
cortical and subcortical innervation (not only dopaminergic) from brainstem or 
basal forebrain nuclei (Bohnen et al., 2006; Shimada et al., 2009) are another 
factor that seems to contribute to functional deficits. Structural techniques may 
not have sufficient sensitivity to detect such changes until these factors amount 
to cell death. We have, nonetheless, been able to detect structural changes in a 
sample of patients that on average did not have advanced PD from either a 
motor or a cognitive perspective. 
In conclusion, we have found evidence that strongly supports previously 
described impairments in the identification of negative facial emotions in PD 
patients. The results of our structural analyses are novel insofar as they reveal 
that the deficits in the recognition of specific facial emotions in PD, rather than 
being solely accompanied by functional changes, have specific structural 
correlates, especially in GM structures but also related to WM microstructural 
integrity. And, to our knowledge, this is the first study to show that the neural 
substrate of the processing of individual emotions can be evaluated through 
structural gray and white matter MRI techniques. 
 
 
 
 
6. REFERENCES 
 
 
1. Aarsland, D., Bronnick, K., Larsen, J.P., Tysnes, O.B., Alves, G., & 
Norwegian ParkWest Study Group. (2009) Cognitive impairment in 
incident, untreated Parkinson disease: the Norwegian ParkWest study. 
Neurology, 72, 1121-1126. 
2. Adolphs R, Tranel D, Damasio H, & Damasio A. (1994). Impaired 
recognition of emotion in facial expressions following bilateral damage to 
the human amygdala. Nature, 372, 669-72. 
3. Adolphs, R. (2002). Neural systems for recognizing emotion. Current 
Opinion in Neurobiology, 12, 169-77. 
4. Adolphs, R., Damasio, H., Tranel, D., Cooper, G., & Damasio, A.R. 
(2000). A role for somatosensory cortices in the visual recognition of 
emotion as revealed by 3-D lesion mapping. The Journal of 
Neuroscience, 20, 2683-2690. 
5. Adolphs, R., Tranel, D., & Damasio, A.R. (2003). Dissociable neural 
systems for recognizing emotions. Brain and Cognition, 52, 61-69. 
6. Andersson, J.L.R., Jenkinson, M., & Smith, S. (2007). Non-linear 
optimisation. FMRIB technical report TR07JA1 from 
www.fmrib.ox.ac.uk/analysis/techrep 
7. Andersson, J.L.R., Jenkinson, M., & Smith, S. (2007). Non-linear 
registration, aka Spatial normalization. FMRIB technical report TR07JA2 
from www.fmrib.ox.ac.uk/analysis/techrep 
8. Arendash, G.W., Millard, W.J., Dunn, A.J., & Meyer, E.M. (1987). Long-
term neuropathological and neurochemical effects of nucleus basalis 
lesions in the rat. Science, 238, 952-956. 
9. Ariatti, A., Benuzzi, F., & Nichelli, P. (2008). Recognition of emotions from 
visual and prosodic cues in Parkinson's disease. Neurological Sciences, 
29, 219-227. 
10. Bechara, A., Damasio, H., & Damasio, A. (2000) Emotion, decision 
making and the orbitofrontal cortex. Cerebral cortex, 10, 295-307. 
11. Beck, A.T., Steer, R.A., & Brown, G.K. (1996). Manual for the Beck 
Depression Inventory-II. San Antonio, TX: Psychological Corporation. 
12. Biseul, I., Sauleau, P., Haegelen, C., Trebon, P., Drapier, D., Raoul, S., 
Drapier, S., Lallement, F., Rivier, I., Lajat, Y., & Verin, M. (2005). Fear 
recognition is impaired by subthalamic nucleus stimulation in Parkinson's 
disease. Neuropsychologia, 43, 1054-1059. 
13. Bohnen, N.I., Kaufer, D.I., Hendrickson, R., Ivanco, L.S., Lopresti, B.J., 
Constantine, G.M., Mathis, C.A., Davis, J.G., Moore, R.Y., & Dekosky, 
S.T. (2006). Cognitive correlates of cortical cholinergic denervation in 
Parkinson's disease and parkinsonian dementia. Journal of Neurology, 
253, 242-247. 
14. Braak, H., Ghebremedhin, E., Rüb, U., Bratzke, H., & Del Tredici, K. 
(2004). Stages in the development of Parkinson's disease-related 
pathology. Cell and Tissue Research, 318, 121-134. 
15. Braak, H., Sandmann-Keil, D., Gai, W., & Braak, E. (1999). Extensive 
axonal Lewy neurites in Parkinson's disease: a novel pathological feature 
revealed by alpha-synuclein immunocytochemistry. Neuroscience 
Letters, 265, 67-69. 
16. Bush, G., Luu, P., & Posner, M.I. (2000). Cognitive and emotional 
influences in anterior cingulate cortex. Trends in Cognitive Sciences, 4, 
215-222.  
17. Calder, A., Young, A. W., Rowland, D., Perrett, D. I., Hodges, J. R., & 
Etcoff, N. L. (1996). Facial emotion recognition after bilateral amygdala 
damage: differentially severe impairment of fear. Cognitive 
Neuropsychology, 13, 699-745. 
18. Calder, A.J., Keane, J., Manes, F., Antoun, N., & Young, A.W. (2000). 
Impaired recognition and experience of disgust following brain injury. 
Nature Neuroscience, 3, 1077-1078. 
19. Calder, A.J., Keane, J., Young, A.W., Lawrence, A.D., Mason, S., & 
Barker, R.A. (2010). The relation between anger and different forms of 
disgust: implications for emotion recognition impairments in Huntington's 
disease. Neuropsychologia, 48, 2719-2729. 
20. Calder, A.J., Keane, J., Lawrence, A.D., & Manes, F. (2004) Impaired 
recognition of anger following damage to the ventral striatum. Brain, 127, 
1958-1969.  
21. Catani, M., Jones, D.K., Donato, R., & Ffytche, D.H. (2003). Occipito-
temporal connections in the human brain. Brain, 126, 2093-2107. 
22. Compta, Y., Parkkinen, L., O’Sullivan, S.O., Vandrovcova, J., Holton, J.L., 
Collins, C., Lashley, T., Kallis, C., Williams, D.R., de Silva, R., Lees, A.J., 
& Revesz, T. (2011) Lewy- and Alzheimer-type pathologies in Parkinson’s 
disease dementia: which is more important? Brain, 134, 1493-1505. 
23. Conforti, L., Adalbert, R., & Coleman, M.P. (2007). Neuronal death: 
where does the end begin? Trends in Neurosciences, 30, 159-166. 
24. Cools, R., Lewis, S.J., Clark, L., Barker, R.A., & Robbins, T.W. (2007). L-
DOPA disrupts activity in the nucleus accumbens during reversal learning 
in Parkinson's disease. Neuropsychopharmacology, 32, 180-189. 
25. Daniel, S.E., & Lees, A.J. (1993). Parkinson's Disease Society Brain 
Bank, London: overview and research. Journal of Neural Transmission. 
Supplementum, 39, 154-172. 
26. Delaveau, P., Salgado-Pineda, P., Wicker, B., Micallef-Roll, J., & Blin, O. 
(2005). Effect of levodopa on healthy volunteers' facial emotion 
perception: an FMRI study. Clinical Neuropharmacology,28, 255-61.  
27. Delaveau, P., Salgado-Pineda, P., Witjas, T., Micallef-Roll, J., Fakra, E., 
Azulay, J.P., & Blin, O. (2009). Dopaminergic modulation of amygdala 
activity during emotion recognition in patients with Parkinson disease. J 
Clinical Psychopharmacology,29, 548-54.  
28. Douaud, G., Smith, S., Jenkinson, M., Behrens, T., Johansen-Berg, H., 
Vickers, J., James, S., Voets, N., Watkins, K., Matthews, P.M., & James, 
A. (2007). Anatomically related grey and white matter abnormalities in 
adolescent-onset schizophrenia. Brain, 130, 2375-2386. 
29. Duffau, H., Gatignol, P., Mandonnet, E., Peruzzi, P., Tzourio-Mazoyer, N., 
& Capelle, L. (2005). New insights into the anatomo-functional 
connectivity of the semantic system: a study using cortico-subcortical 
electrostimulations. Brain, 128, 797-810. 
30. Dujardin, K., Blairy, S., Defebvre, L., Duhem, S., Noël, Y., Hess, U., & 
Destée, A. (2004). Deficits in decoding emotional facial expressions in 
Parkinson's disease. Neuropsychologia, 42, 239-250. 
31. Egner, T., Etkin, A., Gale, S., & Hirsch, J. (2008). Dissociable neural 
systems resolve conflict from emotional versus nonemotional distracters. 
Cerebral Cortex, 18, 1475-1484. 
32. Ekman, P., & Friesen, W.V. (1976). Pictures of Facial Affect. Consulting 
Psychologists Press, Palo-alto. 
33. Emre, M., Aarsland, D., Brown, R., Burn, D.J., Duyckaerts, C., Mizuno, 
Y., Broe, G.A., Cummings, J., Dickson, D.W., Gauthier, S., Goldman, J., 
Goetz, C., Korczyn, A., Lees, A., Levy, R., Litvan, I., McKeith, I., Olanow, 
W., Poewe, W., Quinn, N., Sampaio, C., Tolosa, E., & Dubois, B. (2007). 
Clinical diagnostic criteria for dementia associated with Parkinson's 
disease. Movement Disorders, 22, 1689-1707. 
34. Foltynie, T., Brayne, C.E., Robbins, T.W., & Barker, R.A. (2004). The 
cognitive ability of an incident cohort of Parkinson's patients in the UK. 
The CamPaIGN study. Brain, 127, 550-560. 
35. Fusar-Poli, P., Placentino, A., Carletti, F., Landi, P., Allen, P., Surguladze, 
S., Benedetti, F., Abbamonte, M., Gasparotti, R., Barale, F., Perez, J., 
McGuire, P., & Politi, P. (2009). Functional atlas of emotional faces 
processing: a voxel-based meta-analysis of 105 functional magnetic 
resonance imaging studies. Journal of Psychiatry and Neuroscience, 34, 
418-32. 
36. Gattellaro, G., Minati, L., Grisoli, M., Mariani, C., Carella, F., Osio, M., 
Ciceri, E., Albanese, A., & Bruzzone, M.G. (2009). White matter 
involvement in idiopathic Parkinson disease: a diffusion tensor imaging 
study. American Journal Neuroradiology, 30, 1222-1226. 
37. Goldman, A.I., & Sripada, C.S. (2005). Simulationist models of face-
based emotion recognition. Cognition, 94, 193-213. 
38. Gotham, A.M., Brown, R.G., & Marsen, C.D. (1987). “Frontal” cognitive 
function in patients with Parkinson’s disease “on” and “off” levodopa. 
Brain, 111, 299-321.  
39. Heberlein, A.S., Padon, A.A., Gillihan, S.J., Farah, M.J., & Fellows, L.K. 
(2008). Ventromedial frontal lobe plays a critical role in facial emotion 
recognition. Journal of Cognitive Neuroscience, 20, 721-733. 
40. Hilliard, M.A. (2009). Axonal degeneration and regeneration: a 
mechanistic tug-of-war. Journal of Neurochemistry, 108, 23-32. 
41. Hornak, J., Bramham, J., Rolls, E.T., Morris, R.G., O’Doherty, J., Bullock, 
P.R., & Polkey, C.E. (2003). Changes in emotion after circumscribed 
surgical lesions of the orbitofrontal and cingulate cortices. Brain, 126, 
1691–1712. 
42. Ibarretxe-Bilbao, N., Junque, C., Tolosa, E., Marti, M.J., Valldeoriola, F., 
Bargallo, N., & Zarei, M. (2009). Neuroanatomical correlates of impaired 
decision-making and facial emotion recognition in early Parkinson's 
disease. The European Journal of Neuroscience, 30, 1162-1171. 
43. Jabbi, M., Bastiaansen, J., & Keysers, C. (2008). A common anterior 
insula representation of disgust observation, experience and imagination 
shows divergent functional connectivity pathways. PLoS One, 3, e2939. 
44. Jabbi, M., Swart, M., & Keysers, C. (2007). Empathy for positive and 
negative emotions in the gustatory cortex. Neuroimage, 34, 1744-1753. 
45. Jellinger, K.A., Seppi, K., Wenning, G.K. & Poewe, W. (2002). Impact of 
coexistent Alzheimer pathology on the natural history of Parkinson’s 
disease. Journal of Neural Transmission, 109, 329-339. 
46. Jellinger, K.A. (2008). A critical reappraisal of current staging of Lewy-
related pathology in human brain. Acta Neuropathologica, 116, 1-16. 
47. Kan, Y., Kawamura, M., Hasegawa, Y., Mochizuki, S., & Nakamura, K. 
(2002). Recognition of emotion from facial, prosodic and written verbal 
stimuli in Parkinson's disease. Cortex, 38, 623-630. 
48. Kanwisher, N., McDermott, J., & Chun, M.M. (1997). The fusiform face 
area: a module in human extrastriate cortex specialized for face 
perception. The Journal of Neuroscience, 17, 4302-4311. 
49. Karagulle Kendi, A.T., Lehericy, S., Luciana, M., Ugurbil, K., & Tuite P. 
(2008). Altered diffusion in the frontal lobe in Parkinson disease. 
American Journal Neuroradiology, 29, 501-505. 
50. Krolak-Salmon, P., Hénaff, M.A., Isnard, J., Tallon-Baudry, C., Guénot, 
M., Vighetto, A., Bertrand, O., & Mauguière F. (2003). An attention 
modulated response to disgust in human ventral anterior insula. Annals 
of Neurology, 53, 446-53. 
51. Lawrence, A.D., Calder, A.J., McGowan, S.W., & Grasby, P.M. (2002). 
Selective disruption of the recognition of facial expressions of anger. 
Neuroreport, 13, 881-884. 
52. Lawrence, A.D., Goerendt, I.K., & Brooks, D.J. (2007). Impaired 
recognition of facial expressions of anger in Parkinson's disease patients 
acutely withdrawn from dopamine replacement therapy. 
Neuropsychologia, 45, 65-74. 
53. Leentjens, A.F., Verhey, F.R., Luijckx, G.J., & Troost, J. (2000). The 
validity of the Beck Depression Inventory as a screening and diagnostic 
instrument for depression in patients with Parkinson's disease. 
Movement Disorders, 15, 1221-1224. 
54. Leppanen, J.M. (2006). Emotional information processing in mood 
disorders: a review of behavioral and neuroimaging findings. Current 
Opinion in Psychiatry, 19, 34-39. 
55. Levy, G. (2007). The relationship of Parkinson disease with aging. 
Archives of Neurology, 64, 1242-1246. 
56. Lezak, M.D, Howieson, D.B, & Loring, D.W. (2004). Neuropsychological 
assessment. New York, NY: Oxford 
57. Lu, S., Ahn, D., Johnson, G., Law, M., Zagzag, D., & Grossman, R.I. 
(2004). Diffusion-tensor MR imaging of intracranial neoplasia and 
associated peritumoral edema: introduction of the tumor infiltration index. 
Radiology, 232, 221-228. 
58. Martin, L.J., Pan, Y., Price, A.C., Sterling, W., Copeland, N.G., Jenkins, 
N.A., Price, D.L., & Lee MK. (2006). Parkinson's disease alpha-synuclein 
transgenic mice develop neuronal mitochondrial degeneration and cell 
death. The Journal of Neuroscience, 26, 41-50. 
59. Martino, J., Brogna, C., Robles, S.G., Vergani, F., & Duffau, H. (2010). 
Anatomic dissection of the inferior fronto-occipital fasciculus revisited in 
the lights of brain stimulation data. Cortex, 46, 691-699. 
60. Muslimovic, D., Post, B., Speelman, J.D., & Schmand, B. (2005). 
Cognitive profile of patients with newly diagnosed Parkinson disease. 
Neurology, 65, 1239-1245. 
61. Niedenthal, P.M. (2007). Embodying emotion. Science, 316, 1002-1005. 
62. Pell, M.D., & Leonard, C.L. (2005). Facial expression decoding in early 
Parkinson's disease. Brain Research. Cognitive Brain Research, 23, 327-
340. 
63. Philippi, C.L., Mehta, S., Grabowski, T., Adolphs, R., & Rudrauf, D. 
(2009). Damage to association fiber tracts impairs recognition of the 
facial expression of emotion. The Journal of Neuroscience, 29, 15089-
15099. 
64. Phillips, M.L., Young, A.W., Senior, C., Brammer, M., Andrew, C., Calder, 
A.J., Bullmore, E.T., Perrett, D.I., Rowland, D., Williams, S.C., Gray, J.A., 
& David, A.S. (1997). A specific neural substrate for perceiving facial 
expressions of disgust. Nature, 389, 495-498. 
65. Pitcher, D., Garrido, L., Walsh, V., & Duchaine, B.C. (2008). Transcranial 
magnetic stimulation disrupts the perception and embodiment of facial 
expressions. Journal of Neuroscience, 28, 8929-33. 
66. Raff, M.C., Whitmore, A.V., & Finn, J.T. (2002). Axonal self-destruction 
and neurodegeneration. Science, 296, 868-871. 
67. Reijnders, J.S., Ehrt, U., Weber, W.E., Aarsland, D., & Leentjens, A.F. 
(2008). A systematic review of prevalence studies of depression in 
Parkinson's disease. Movement Disorders, 23, 183-189. 
68. Rudrauf, D., David, O., Lachaux, J.P., Kovach, C.K., Martinerie, J., 
Renault, B., & Damasio, A. (2008). Rapid interactions between the 
ventral visual stream and emotion-related structures rely on a two-
pathway architecture. The Journal of Neuroscience, 28, 2793-2803. 
69. Rueckert, D., Sonoda, L.I., Hayes, C., Hill, D.L.G., Leach, M.O., & 
Hawkes, D.J. (1999). Non-rigid registration using free-form deformations: 
Application to breast MR images. IEEE Transactions on Medical Imaging, 
18, 712-721. 
70. Shimada, H., Hirano, S., Shinotoh, H., Aotsuka, A., Sato, K., Tanaka, N., 
Ota, T., Asahina, M., Fukushi, K., Kuwabara, S., Hattori, T., Suhara, T., & 
Irie, T. (2009). Mapping of brain acetylcholinesterase alterations in Lewy 
body disease by PET. Neurology, 73, 273-278. 
71. Slaughter, J.R., Slaughter, K.A., Nichols, D., Holmes, S.E., & Martens, 
M.P. (2001). Prevalence, clinical manifestations, etiology, and treatment 
of depression in Parkinson's disease. The Journal of Neuropsychiatry 
and Clinical Neurosciences, 13, 187-196. 
72. Smith, S.M., Jenkinson, M., Johansen-Berg, H., Rueckert, D., Nichols, 
T.E., Mackay, C.E., Watkins, K.E., Ciccarelli, O., Cader, M.Z., Matthews, 
P.M., & Behrens, T.E. (2006). Tract-based spatial statistics: voxelwise 
analysis of multi-subject diffusion data. Neuroimage, 31, 1487-1505. 
73. Smith, S.M., Jenkinson, M., Woolrich, M.W., Beckmann, C.F., Behrens, 
T.E., Johansen-Berg, H., Bannister, P.R., De Luca, M., Drobnjak, I., 
Flitney, D.E., Niazy, R.K., Saunders, J., Vickers, J., Zhang, Y., De 
Stefano, N., Brady, J.M., & Matthews, P.M. (2004). Advances in 
functional and structural MR image analysis and implementation as FSL. 
Neuroimage, 23(Suppl. 1), S208-S219. 
74. Sprengelmeyer, R., Young, A.W., Mahn, K., Schroeder, U., Woitalla, D., 
Büttner, T., Kuhn, W., & Przuntek H. (2003). Facial expression 
recognition in people with medicated and unmedicated Parkinson's 
disease. Neuropsychologia, 41, 1047-1057. 
75. Suzuki, A., Hoshino, T., Shigemasu, K., & Kawamura, M. (2006). Disgust-
specific impairment of facial expression recognition in Parkinson's 
disease. Brain, 129, 707-717. 
76. Tessitore, A., Hariri, A.R., Fera, F., Smith, W.G., Chase, T.N., Hyde, T.M., 
Weinberger, D.R., & Mattay, V.S. (2002). Dopamine modulates the 
response of the human amygdala: a study in Parkinson's disease. The 
Journal of Neuroscience, 22, 9099-9103. 
77. Tomlinson, C.L., Stowe, R., Patel, S., Rick, C., Gray, R., & Clarke, C.E. 
(2010) Systematic review of levodopa equivalency reporting in 
Parkinson’s disease. Movement Disorders, 25, 2649-2653. 
78. Vernooij, M.W., Ikram, M.A., Vrooman, H.A., Wielopolski, P.A., Krestin, 
G.P., Hofman, A., Niessen, W.J., Van der Lugt, A., & Breteler, M.M. 
(2009). White matter microstructural integrity and cognitive function in a 
general elderly population. Archives of General Psychiatry, 66, 545-553. 
79. Wicker, B., Keysers, C., Plailly, J., Royet, J.P., Gallese, V., & Rizzolatti, 
G. (2003). Both of us disgusted in my insula: the common neural basis of 
seeing and feeling disgust. Neuron, 40, 655-664. 
80. Worsley, K.J., Marrett, S., Neelin, P., Vandal, A.C., Friston, K.J., & Evans, 
A.C. (1996). A unified statistical approach for determining significant 
signals in images of cerebral activation. Human Brain Mapping, 4, 58–73. 
81. Yip, J.T., Lee, T.M., Ho, S.L., Tsang, K.L., & Li, L.S. (2003). Emotion 
recognition in patients with idiopathic Parkinson's disease. Movement 
Disorders, 18, 1115-1122. 
 
 
 Figure 1 
 Figure 2 
 
